{"schema_version":"secwatch.filing_event.v1","accession":"0000879169-26-000016","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.889342+00:00","generated_at":"2026-05-15T08:56:57.182440+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Incyte appoints Cagnoni as President, integrates U.S. commercial; Trotta departs","bullets":["Pablo Cagnoni named President, Incyte and Global Head of R&D; replaces Bill Meury as President; Meury remains CEO.","Steven Stein promoted to EVP, Chief Medical Officer and Head of Late-stage Development.","Mohamed Issa becomes EVP and Head of U.S. Commercial; U.S. oncology and immunology teams integrated.","Matteo Trotta, EVP and GM of U.S. Dermatology, will leave Incyte after a transition period.","No changes to compensation for the impacted executives in connection with these title changes."],"urls":{"canonical":"https://secwatch.observer/filing/0000879169-26-000016","json":"https://secwatch.observer/filing/0000879169-26-000016.json","markdown":"https://secwatch.observer/filing/0000879169-26-000016.md","text":"https://secwatch.observer/filing/0000879169-26-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000087916926000016/0000879169-26-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000087916926000016/incy-20260325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:56:57.182440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}